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Summary of ICB IV 
Workshop 3: 




Integrated and Continuous Bioprocessing IV 
Cape Cod, Massachusetts. October 9, 2019
Moderators: Jessica Molek, GSK
Daisie Ogawa, Boehringer Ingelheim
Workshop 3 
Abstract
Utilization of traditional batch processes is so entrenched in the biopharmaceutical 
production landscape that transitioning to a new approach, no matter how efficient 
or productive, is challenging. Integrated, continuous manufacturing (CM) promises 
higher per-bioreactor vessel productivity, smaller downstream footprints, and more 
consistent product quality than batch processing. However, realization of these 
benefits depends greatly on the scenario at hand and the proposed manufacturing 
strategy. A compelling business case must be presented in order to consider making 
the transition to CM from the traditional manufacturing approach. The degree of 
process integration, the target scale and facility vision toward automation, as well as 
the strategy toward implementation with respect to portfolio maturity are key actors 
to consider. This workshop will explore some of these key strategic factors and how 
they influence the business case for CM. 
Agenda
 Workshop Welcome
 Introductions of Co-chairs 
 Pre-workshop Survey 
 Review of survey questions 1-3
 Reading of workshop prompts 1-5
 20 minutes of break-out discussions
 2 tables for each of prompts 1-4, no takers for prompt 5
 50 minutes of group discussion (10 minutes per prompt)









2. How far along is your company in adopting Continuous Manufacturing?
a. not pursuing at all
b. very early- ie paper-based thought experiment
c. early- hands-on lab-based process development
d. mid- preparing for clinical
e. mid/late- clinical mfg has occurred 
f. commercial 
3. Do you foresee GMP manufacturing using a continuous manufacturing vendor-
supplied platform or a custom, in-house developed platform? 
a. Vendor(s) 
b. In-house
4. What do you feel is the single biggest benefit of continuous? 

















Not Pursuing At All Very Early (paper based thought)
Early (hands on - lab based) Mid (prepare for clinical)









1. What do you think are the key business drivers currently influencing the 
biopharmaceutical industry: footprint reduction, speed to market, speed of 
production, speed of expansion, improved product quality, reduced capex 
or opex, other? In what way does continuous manufacturing meet the 
challenges associated with these business drivers? 
2. What is the ideal level of integration for unit operations? Where are the 
biggest benefits to integration (eg linking perfusion bioreactor to capture 
columns)? What might be some of the main business case arguments 
which inform these decisions?
3. What are the major risks for a business to add capability of integrated 
continuous processing: replace/retrofitting of existing facilities, investment 
in greenfield, regulatory concerns, technology development, supply chain 
security, etc.
4. What stage of a program is best suited for implementation of continuous 
processing (early, late, post approval) and why? Does the degree of 
integration change based on the time of implementation in the product 
lifecycle? 
5. Batch definition and associated analytical testing strategy has a major 
impact on the overall cost, speed to market, and supply chain strategy. 
How should the definition and strategy be defined to balance the benefits 
and risks associated with continuous manufacturing? 
Prompt 1-
What are the 
key business 
drivers for ICB?
Reduction in Cost of Goods/Risk
• not over-producing at FB large scale
• for low-demand modalities
• Reducing CapEx/OpEx (especially by reducing size of facility)








• mAb- high dose requirements, large patient populations. Higher titer is advantage here
Cost pressure for healthcare
 Improved and/or more consistent product quality, enabled by PAT
Alleviate capacity constraints of network
Streamline control strategy (scale-out vs scale-up no change in process)
At-scale development
De-bottlenecking DSP
Demonstrated benefits in other industries (auto, semiconductor, etc)
 Many points refer to extensive implementation of continuous, continuous/connected 
Upstream, and/or downstream may be more easily quantified
Prompt 2-




 The problem being solved by integration often defines level of 
integration, each company will dictate the extent of integration for 
themselves. May be based on stage at which continuous is first used
 Vial to vial (ideal)– lots of back-and-forth discussion on this point, 
generally agreed that it really depends on the molecule and indication
 Including analytics
 Challenge – if have different Drug Product presentation could be 
different
 API Shelf time is now not applicable so inventory only controlled on DP 
Stability
 Process until stable intermediate for mAbs
 Reduces affinity capture resin costs
 Most beneficial for a new facility or a new process
 Most beneficial steps to connect:
 Perfusion- capture (especially from an intensified perfusion bioreactor)
 No harvest, no centrifuge or filters
 Buffer prep from concentrate
 (stable hold points) neutralized VI
 Automated sampling
 Analytics on the floor
 Polishing-rest
Prompt 3-
What are the 




 Retrofitting: costs and 
downtime
 Capex concerns at outlay to 
convert
 Equipment
 Familiarity of new 
equipment and processes 
 Immaturity of technology 
 Lack of standardization of 
equipment 
 Need to develop relationships 
with new vendors
 Nonstandardized supply 
chain components
 Management of inventory
 Highly reliant on single 
sources components
 Supplying both batch and ICB 
with enough production to fill 
all facilities. 
 Having to decide which type 
of facility to develop toward 
– two parallel tracks?





 Comparability (late stage)
 Bioburden control
 Highly automated
 How to handle deviations
 How to handle pauses when 
running in constant flow
 Optimization for changing 
portfolio
 Quantification of benefits
 Product / pipeline 
requirements
 Importance of Cost reduction
 Automation
 Requires platform from the 
beginning to be automated
 Automation expertise 
required
 Lack of standardization 
exists




stage is best 





 Implementation during product lifecycle is based on portfolio 
distribution and capacity availability
 Why Early Phase
 Decrease comparability risk and will allow program to develop over time
 FB to perfusion transition during late stage could be challenge
 Many technologies well established, can be adopted early
 Regulatory expectation still unknown
 Attrition in the clinic can delay tech introduction
 Why Late Phase
 Takes speed to clinic off critical path
 Ability to achieve a lower additional capex cost
 General Challenges:
 Steady State Perfusion can be difficult to achieve, increase risk of 
failures/ interruptions, could cause bigger timeline delays
 Infrastructure for ICB takes time to develop
 Shorter dynamic perfusion might be faster for timeline to clinic, but may 
be hard to transition to steady state perfusion during late stage 
development
 Novel modalities may be more difficult to express/ purify
#5 Batch 
definition
 Batch definition was not problematic
 Batch could be defined in multiple different ways, but based on 
company need
 Sample load could be decreased if deemed to be the best way to 
define a batch
 Flexibility of batch is available




 No “one size fits all” solution, business case highly dependent on 
individual company needs
 Benefits depend on portfolio (stage and modality focus) and 
current capacity/capabilities
 Cost of goods (including CapEx, $/g, g/m2) reduction by ICB was 
brought up repeatedly, by multiple companies as a key driver
 Business cases have been successful – progression over two years 
on implementation (including GMP implementation session)
